Press Releases

8/19/2024
Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain
7/16/2024
Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain
6/3/2024
Aruna Bio Annouces Appointment of Lynn Swann to its Board of Directors
3/18/2024
Aruna Bio to Participate in Upcoming Investor Conferences
3/4/2024
Aruna Bio Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
1/16/2024
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
10/10/2023
Aruna Bio to Participate in the BIO Investor Forum in October 2023
9/7/2023
Aruna Bio Announces Preclinical Results from Pilot Study Evaluating AB126 for the Treatment of Amyotrophic Lateral Sclerosis
9/5/2023
Aruna Bio Announces Presentation on Treatment Opportunities for its Neural Exosome Platform and Lead Program, AB126 at the Exosome Based Therapeutic Development Summit
8/15/2023
Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition
3/28/2023
Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Receives Entrepreneur Distinction from The University System of Georgia Board of Regents
12/19/2022
Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors
10/6/2022
Aruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit
6/13/2022
Aruna Bio Announces Issuance of a New Composition of Matter Patent Covering Neural Exosomes in Japan
5/31/2022
Aruna Bio Advances Therapeutic Development for Traumatic Brain Injury
4/27/2022
Aruna Bio Appoints Stephen From as Chief Executive Officer
11/22/2021
Aruna Bio to Present at the Piper Sandler 33rd Annual Healthcare Conference
9/23/2021
Aruna Bio Appoints John Richard to Board of Directors
9/13/2021
Aruna Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Healthcare Life Sciences & MedTech Summit
5/26/2020
Aruna Bio to Present at 2020 Jefferies Conference
12/4/2019
Aruna Bio Appoints Dr. James Paskavitz as Vice President of Research and Development
11/21/2019
Aruna Bio to Present at the 31st Annual Piper Jaffray Healthcare Conference
11/13/2019
Aruna Bio Appoints Dr. Renee Boerner as Vice President of Regulatory Affairs
10/10/2019
Aruna Bio Awarded $4.5 Million SBIR Phase II Grant to Support Development of Neural Exosome AB126
9/12/2019
Aruna Bio to Present at Exosome Based Therapeutic Development Summit
8/8/2019
Aruna Bio Appoints Tony Townley to Board of Directors
7/24/2019
Aruna Bio Raises $13 Million in Common Stock Financing
5/22/2019
Aruna Bio to Provide Corporate Update and Participate on a Panel at the 2019 BIO International Convention
3/18/2019
Aruna Bio Appoints Al Medwar as Executive Vice President, Corporate and Commercial Development
1/15/2019
Aruna Bio Appoints Dr. Mark Sirgo as Chief Executive Officer
9/27/2018
Aruna Bio Raises $5.3 Million to Fuel Growth and Innovation for its Neural Exosome Therapeutic Platform
5/31/2018
Aruna Biomedical Appoints Industry Veteran Skip Irving to Board of Directors
5/24/2018
Aruna Biomedical to Present and Participate on a Panel at 2018 BIO International Convention
4/25/2018
Aruna Biomedical Announces Oral Presentation of Preclinical Data at ISEV 2018
4/12/2018
Aruna Biomedical Announces Publication of Study in Stroke that Reports Exosomes Improved Tissue and Functional Recovery in Pig Model of Ischemic Stroke
1/3/2018
Aruna Biomedical Launches New Class of Exosome Biologics to Treat Central Nervous System and Neurodegenerative Disorders